South Dakota-based Covid-19 transgenic cow antibody startup claims its first PhIII win
SAB Biotherapeutics, known for collecting and distilling antibodies from cows with humanized immune systems, on Wednesday said a Phase III trial it ran for its potential Covid-targeted polyclonal antibody demonstrated benefit in sustained symptom resolution in patients with the Omicron variant.
The NIH-run study put the SAB treatment up against Regeneron’s monoclonal antibody — known as REGEN-COV, which was pulled from the market in January 2022 due to its ineffectiveness against Omicron — in non-hospitalized people with Covid-19 who were at high-risk for severe outcomes.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.